ERBB2 and breast cancer: The prognosis of patients with BC and BMs remains quite poor, with an mOS of 8.7 months, but there are significant differences according to the molecular subtypes, ranging from 9.3, 16.5, and 21.6 to 4.9 months in the luminal, HER2-positive and TNBC group, respectively [66].